Loading stock data…
$0.34-0.09 (-20.63%)
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.
Karyopharm Therapeutics Inc. in the Healthcare sector is trading at $0.34 with a market capitalization of $43M. Wall Street consensus targets $7.25 (4 analysts), implying a +2038.6% move over the next 12 months. The stock is currently near its 52-week low of $0.34, remaining 94.8% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 1 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33.43M↓ | $35.07M↑ | $34.08M↓ | $44.04M↑ | $37.93M |
| Gross Profit | $32.35M↓ | $33.72M↑ | $32.59M↓ | $41.93M↑ | $36.88M |
| Operating Income | -$22.53M↑ | -$26.76M↓ | -$17.84M↓ | -$15.22M↑ | -$24.39M |
| Net Income | -$67.02M↓ | -$22.39M↑ | -$102.20M↓ | -$33.13M↑ | -$37.25M |
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develop...